P01-491

ARE PLATELET SEROTONIN LEVELS AND PLATELET MAO ACTIVITY THE BIOLOGICAL MARKERS FOR THE PROGRESS OF ALZHEIMER'S DISEASE? P. Presečki¹, D. Muck Šeler², N. Mimica^{3,4}, M. Mustapić², N. Pivac², M. Mihanović¹, G. Nedić², V. Folnegović-Šmalc^{3,4}

¹Department of Psychiatry, Psychiatric Hospital Sveti Ivan, ²Division of Molecular Medicine, Ruđer Bošković Institute, ³University Department of Psychiatry, Psychiatric Hospital Vrapče, ⁴School of Medicine, University of Zagreb, Zagreb, Croatia

Introduction: Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder with unclear aetiology. Cognitive impairment and the behavioral disturbances in patients with AD might be associated with altered serotonergic system.

Objectives: Platelet serotonin (5-HT) levels and platelet monoamine oxidase type B (MAO-B) activity might be the biological markers for the progress of AD.

Aims: To determine platelet 5-HT concentrations and MAO-B activity in female patients with mild, moderate or severe stage of AD and sex and age matched healthy controls. Methods: The study included 106 female patients with the diagnosis of probable AD (DSM-IV-TR and NINCDS-ADRDA criteria), subdivided according to the Mini Mental State Examination (MMSE) score in early (MMSE 26-18), middle (MMSE 17-10) and late (MMSE 9-0) phase of AD. Control group consisted of 102 healthy elderly women (MMSE 30-27). Platelet 5-HT concentrations and MAO-B activity were determined using spectrofluorimetric methods

Results: Platelet 5-HT concentrations and MAO-B activity were similar between all patients with AD and healthy controls. Patients in the late phase of AD had significantly (p< 0.05) lower platelet 5-HT concentrations and MAO-B activity than patients in other phases of AD and healthy controls. The significant correlations were found between MMSE scores and platelet 5-HT concentrations, MAO-B activity and age.

Conclusion: The results suggest that platelet 5-HT concentration and MAO-B activity might be the peripheral biological markers for the severity and/or clinical progress of AD.